{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:33:56Z","timestamp":1773297236828,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008719","name":"Movember Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008719","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000927","name":"Prostate Cancer Foundation of Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000927","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13014-019-1359-0","type":"journal-article","created":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T12:04:29Z","timestamp":1567685069000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["NaF PET\/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7796-8472","authenticated-orcid":false,"given":"Nicholas","family":"Hardcastle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Yu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Callahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Selbie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farshad","family":"Foroudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarat","family":"Chander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent","family":"Chesson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Declan G.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Kron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shankar","family":"Siva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,5]]},"reference":[{"issue":"1","key":"1359_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.euf.2017.10.014","volume":"4","author":"SP Kelly","year":"2018","unstructured":"Kelly SP, Anderson WF, Rosenberg PS, Cook MB. Past, current, and future incidence rates and burden of metastatic prostate Cancer in the United States. Eur Urol Focus. 2018;4(1):121\u20137. \n                    https:\/\/doi.org\/10.1016\/j.euf.2017.10.014\n                    \n                  .","journal-title":"Eur Urol Focus"},{"issue":"5","key":"1359_CR2","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.clgc.2018.05.016","volume":"16","author":"E Mazzone","year":"2018","unstructured":"Mazzone E, Preisser F, Nazzani S, et al. Location of metastases in contemporary prostate Cancer patients affects Cancer-specific mortality. Clin Genitourin Cancer. 2018;16(5):376\u2013384.e1. \n                    https:\/\/doi.org\/10.1016\/j.clgc.2018.05.016\n                    \n                  .","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"1359_CR3","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.ijrobp.2016.01.032","volume":"95","author":"JL Muldermans","year":"2016","unstructured":"Muldermans JL, Romak LB, Kwon ED, Park SS, Olivier KR. Stereotactic body radiation therapy for Oligometastatic prostate Cancer. Int J Radiat Oncol Biol Phys. 2016;95(2):696\u2013702. \n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2016.01.032\n                    \n                  .","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1359_CR4","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ijrobp.2018.08.027","volume":"103","author":"P Sutera","year":"2019","unstructured":"Sutera P, Clump DA, Kalash R, et al. Initial results of a multicenter phase 2 trial of stereotactic ablative radiation therapy for Oligometastatic Cancer. Int J Radiat Oncol. 2019;103(1):116\u201322. \n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2018.08.027\n                    \n                  .","journal-title":"Int J Radiat Oncol"},{"key":"1359_CR5","doi-asserted-by":"publisher","unstructured":"Bridget Koontz BF, Editor A. Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer: The Hunt for the Silver Bullet. doi:\n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2017.05.020\n                    \n                  .","DOI":"10.1016\/j.ijrobp.2017.05.020"},{"issue":"2","key":"1359_CR6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s11307-011-0486-2","volume":"14","author":"A Iagaru","year":"2012","unstructured":"Iagaru A, Mittra E, Dick DW, Gambhir SS. Prospective evaluation of 99mTc MDP scintigraphy, 18F NaF PET\/CT, and 18F FDG PET\/CT for detection of skeletal metastases. Mol Imaging Biol. 2012;14(2):252\u20139. \n                    https:\/\/doi.org\/10.1007\/s11307-011-0486-2\n                    \n                  .","journal-title":"Mol Imaging Biol"},{"issue":"1","key":"1359_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3109\/0284186X.2015.1027411","volume":"55","author":"I Jambor","year":"2016","unstructured":"Jambor I, Kuisma A, Ramadan S, et al. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT\/CT,18F-NaF PET\/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial. Acta Oncol (Madr). 2016;55(1):59\u201367. \n                    https:\/\/doi.org\/10.3109\/0284186X.2015.1027411\n                    \n                  .","journal-title":"Acta Oncol (Madr)"},{"issue":"4","key":"1359_CR8","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.clgc.2016.12.020","volume":"15","author":"Y Miyoshi","year":"2017","unstructured":"Miyoshi Y, Uemura K, Kawahara T, et al. Prognostic value of automated bone scan index in men with metastatic castration-resistant prostate Cancer treated with enzalutamide or Abiraterone acetate. Clin Genitourin Cancer. 2017;15(4):472\u20138. \n                    https:\/\/doi.org\/10.1016\/j.clgc.2016.12.020\n                    \n                  .","journal-title":"Clin Genitourin Cancer."},{"issue":"9","key":"1359_CR9","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1007\/s12149-013-0749-x","volume":"27","author":"H Wakabayashi","year":"2013","unstructured":"Wakabayashi H, Nakajima K, Mizokami A, et al. Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases. Ann Nucl Med. 2013;27(9):802\u20137. \n                    https:\/\/doi.org\/10.1007\/s12149-013-0749-x\n                    \n                  .","journal-title":"Ann Nucl Med"},{"issue":"2","key":"1359_CR10","first-page":"287","volume":"47","author":"E Even-Sapir","year":"2006","unstructured":"Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET\/CT. J Nucl Med. 2006;47(2):287\u201397 doi:47\/2\/287.","journal-title":"J Nucl Med"},{"issue":"12","key":"1359_CR11","first-page":"1800","volume":"42","author":"H Schirrmeister","year":"2001","unstructured":"Schirrmeister H, Glatting G, Hetzel J, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18) F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med. 2001;42(12):1800\u20134 \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11752076\n                    \n                  . Accessed 21 Aug 2018.","journal-title":"J Nucl Med"},{"issue":"1","key":"1359_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0001-2998(72)80005-9","volume":"2","author":"M Blau","year":"1972","unstructured":"Blau M, Ganatra R, Bender MA. 18 F-fluoride for bone imaging. Semin Nucl Med. 1972;2(1):31\u20137 \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/5059349\n                    \n                  . Accessed 6 Dec 2018.","journal-title":"Semin Nucl Med"},{"issue":"1","key":"1359_CR13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.2967\/jnumed.106.037200","volume":"49","author":"FD Grant","year":"2007","unstructured":"Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med. 2007;49(1):68\u201378. \n                    https:\/\/doi.org\/10.2967\/jnumed.106.037200\n                    \n                  .","journal-title":"J Nucl Med"},{"issue":"2","key":"1359_CR14","first-page":"272","volume":"45","author":"E Even-Sapir","year":"2004","unstructured":"Even-Sapir E, Metser U, Flusser G, et al. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET\/CT and comparison between 18F-fluoride PET and 18F-fluoride PET\/CT. J Nucl Med. 2004;45(2):272\u20138.","journal-title":"J Nucl Med"},{"issue":"12","key":"1359_CR15","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/nrclinonc.2012.188","volume":"9","author":"RJ Hicks","year":"2012","unstructured":"Hicks RJ, Hofman MS. Is there still a role for SPECT-CT in oncology in the PET-CT era? Nat Rev Clin Oncol. 2012;9(12):712\u201320. \n                    https:\/\/doi.org\/10.1038\/nrclinonc.2012.188\n                    \n                  .","journal-title":"Nat Rev Clin Oncol"},{"key":"1359_CR16","doi-asserted-by":"publisher","unstructured":"Arvola S, Jambor I, Kuisma A, et al. Comparison of standardized uptake values between 99m Tc-HDP SPECT\/CT and 18 F-NaF PET\/CT in bone metastases of breast and prostate cancer. Eur J Nucl Med Mol Imaging Res. 2019;9(1). \n                    https:\/\/doi.org\/10.1186\/s13550-019-0475-z\n                    \n                  .","DOI":"10.1186\/s13550-019-0475-z"},{"key":"1359_CR17","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1016\/j.eururo.2018.06.004","volume":"0","author":"S Siva","year":"2018","unstructured":"Siva S, Bressel M, Murphy DG, et al. Stereotactic Abative body radiotherapy (SABR) for Oligometastatic prostate Cancer: a prospective clinical trial. Eur Urol. 2018;0:0. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2018.06.004\n                    \n                  .","journal-title":"Eur Urol"},{"issue":"5","key":"1359_CR18","doi-asserted-by":"publisher","first-page":"e597","DOI":"10.1016\/j.ijrobp.2012.03.009","volume":"83","author":"BW Cox","year":"2012","unstructured":"Cox BW, Spratt DE, Lovelock M, et al. International spine radiosurgery consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery. Int J Radiat Oncol. 2012;83(5):e597\u2013605. \n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2012.03.009\n                    \n                  .","journal-title":"Int J Radiat Oncol."},{"issue":"2","key":"1359_CR19","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.ijrobp.2018.02.005","volume":"101","author":"M Cysouw","year":"2018","unstructured":"Cysouw M, Bouman-Wammes E, Hoekstra O, et al. Scientific letter prognostic value of [ 18 F]-Fluoromethylcholine positron emission tomography\/computed tomography before stereotactic body radiation therapy for Oligometastatic prostate Cancer radiation oncology. Int J Radiat Oncol Biol Phys. 2018;101(2):406\u201310. \n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2018.02.005\n                    \n                  .","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1359_CR20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.eururo.2018.03.030","volume":"74","author":"S Han","year":"2018","unstructured":"Han S, Woo S, Kim YJ, Suh CH. Impact of 68 Ga-PSMA PET on the Management of Patients with prostate Cancer: a systematic review and meta-analysis. Eur Urol. 2018;74(2):179\u201390. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2018.03.030\n                    \n                  .","journal-title":"Eur Urol"},{"issue":"11","key":"1359_CR21","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1007\/s00259-018-4058-4","volume":"45","author":"HD Zacho","year":"2018","unstructured":"Zacho HD, Nielsen JB, Afshar-Oromieh A, et al. Prospective comparison of68Ga-PSMA PET\/CT,18F-sodium fluoride PET\/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45(11):1884\u201397. \n                    https:\/\/doi.org\/10.1007\/s00259-018-4058-4\n                    \n                  .","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"1359_CR22","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1007\/s00259-018-4048-6","volume":"45","author":"C Uprimny","year":"2018","unstructured":"Uprimny C, Svirydenka A, Fritz J, et al. Comparison of [68Ga]Ga-PSMA-11 PET\/CT with [18F] NaF PET\/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy. Eur J Nucl Med Mol Imaging. 2018;45(11):1873\u201383. \n                    https:\/\/doi.org\/10.1007\/s00259-018-4048-6\n                    \n                  .","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1359_CR23","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/1754-9485.12590","volume":"61","author":"S Siva","year":"2017","unstructured":"Siva S, Callahan J, Pryor D, Martin J, Lawrentschuk N, Hofman MS. Utility of 68 Ga prostate specific membrane antigen - positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma. J Med Imaging Radiat Oncol. 2017;61(3):372\u20138. \n                    https:\/\/doi.org\/10.1111\/1754-9485.12590\n                    \n                  .","journal-title":"J Med Imaging Radiat Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-019-1359-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13014-019-1359-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-019-1359-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T23:19:32Z","timestamp":1599175172000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-019-1359-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,5]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1359"],"URL":"https:\/\/doi.org\/10.1186\/s13014-019-1359-0","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,5]]},"assertion":[{"value":"17 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This prospective interventional clinical trial was approved by the Peter MacCallum Cancer Centre institutional review board, Melbourne, Australia (POPSTAR, \u2018Pilot Study of patients with Oligometastases from Prostate cancer treated with STereotactic Ablative Radiotherapy\u2019, Universal Trial Number U1111\u20131140-7563). All patients signed informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"164"}}